For All The Latest Medical News, Health News, Research News, COVID-19 News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Cardiology News, Epigenetic News, Cancer News, Doctor News, Hospital News

BREAKING NEWS
Nikhil Prasad  Fact checked by:Thailand Medical News Team May 02, 2024  6 months, 1 week, 5 days, 6 hours ago

Scientist From China Discover That Guanylate-Binding Protein 1 Inhibits H5N1 Induced Inflammatory Issues Via Its GTPase Activity

1916 Shares
facebook sharing button Share
twitter sharing button Tweet
linkedin sharing button Share
Scientist From China Discover That Guanylate-Binding Protein 1 Inhibits H5N1 Induced Inflammatory Issues Via Its GTPase Activity
Nikhil Prasad  Fact checked by:Thailand Medical News Team May 02, 2024  6 months, 1 week, 5 days, 6 hours ago
H5N1 News: The interaction between inflammatory factors and influenza A virus infections is a critical factor contributing to host mortality. Guanylate-binding protein 1 (gGBP1) has shown promise in downregulating cytokine production induced by influenza viruses, particularly H5N1. This H5N1 News report delves into the innate immune defense mechanisms of gGBP1 during H5N1 infection, highlighting its potential in mitigating inflammatory responses and providing insights for disease prevention and control.


Guanylate-Binding Protein 1 Inhibits H5N1 Induced Inflammatory Issues Via Its GTPase Activity
Expression of guanylate-binding protein 1 (gGBP1) in transfected RAW264.7 cells as determined by western blotting and immunofluorescence assays (A). 1: pCMV-Lg/RAW264.7 cells, 2: pCMV-Hel/RAW264.7 cells, M: marker. (B–I) The mRNA levels of CCL2, CCL5, IL-10, IL-1β, IL-6, mGBP1, TNF-α, and CXCL10 and the protein expression levels of CCL2 and CXCL10 (I and J) in pCMV-GBP1/RAW264.7 cells infected with H5N1 (MOI = 0.01). Effect of gGBP1 on cell proliferation, with or without TNF-α and IFN-γ treatment (L and M). Values are expressed as the mean ± SD of four individual experiments. (*P < 0.05, ⁎⁎0.01 < P < 0.05, ⁎⁎⁎P < 0.01 vs. MOCK; ##0.01 < P < 0.05, ###P < 0.01 vs. pCMV-HA/RAW264.7 cells)

Challenges Posed By influenza A Viruses (IAV)
Influenza viruses pose significant challenges, with the influenza A virus (IAV) being particularly notorious for its high mortality rates. The cytokine storm triggered by IAV infections often leads to acute lung injury (ALI) and severe respiratory complications. Vaccination remains the primary preventive measure, yet the virus's mutability limits vaccine efficacy. Understanding the immune responses during infection, especially with pathogens like highly pathogenic avian influenza H5N1, is crucial for devising effective control strategies.
 
The Role of Inflammatory Factors in IAV Infections
IAV, especially H5N1, elicits a robust inflammatory response characterized by elevated pro-inflammatory cytokines like TNF-α, IL-6, and IP-10. While these cytokines are pivotal in combating pathogens, their excessive production can lead to tissue damage and worsen disease outcomes. Balancing cytokine levels is thus essential for mounting an effective defense without causing collateral damage.

Guanylate-Binding Proteins (GBPs): Guardians of Innate Immunity
GBPs, induced by interferons, play crucial roles in innate immune responses against various pathogens, including viruses. GBP1, with its GTPase activity, has garnered attention for its antiviral properties against diverse pathogens. Studies have highlighted its role in inhibiting viral replication and modulating immune responses.
 
>Guanylate-Binding Proteins: Guardians of Host Defense
Guanylate-binding proteins (GBPs) are a family of interferon-inducible proteins that play pivotal roles in host defense against various pathogens, including viruses. Among the GBPs, guanylate-binding protein 1 (gGBP1) has emerged as a key player in modulating immune responses and exerting antiviral effects. By harnessing its GTPase activity, gGBP1 regulates intracellular signaling pathways involved in immune defense mechanisms.
 
Exploring gGBP1's Mechanisms in Influenza Infection
Research demonstrates that gGBP1 inhibits early replication of H5N1 and suppresses the production of cytokines like CCL2 and CXCL10 induced by the virus. This inhibition is attributed to gGBP1's GTPase activity and its C-terminal α-helix structure, which regulates cell proliferation. By targeting key amino acid residues, gGBP1 exerts inhibitory effects on inflammatory factors, paving the way for potential therapeutic interventions.
 
Study Findings: Unraveling gGBP1's Impact
-Knocking Out gGBP1 and Viral Replication
Knockout of gGBP1 promoted early replication of H5N1, emphasizing its role in controlling viral spread during the infection's initial stages. This finding underscores the significance of gGBP1 in limiting viral proliferation and subsequent pathogenesis.
 
-Effect of gGBP1 Gene Knockdown on Inflammatory Factors
In H5N1-infected cells lacking gGBP1, there was a notable increase in cytokines like CCL2 and CXCL10, indicative of heightened inflammatory responses. Reintroducing gGBP1 attenuated cytokine production, highlighting its regulatory role in modulating inflammatory cascades.
 
-gGBP1's Inhibitory Effects in Macrophages
In macrophages infected with H5N1, gGBP1 suppressed CCL2 and CXCL10 expression, showcasing its ability to dampen inflammatory signals. Additionally, gGBP1 inhibited macrophage proliferation induced by these cytokines, further mitigating inflammatory amplification.
 
Mechanisms Underlying gGBP1's Actions
Mutational analysis revealed critical amino acid residues, particularly lysine at position 51, essential for gGBP1's GTPase activity. The C-terminal α-helix structure influenced cell proliferation, while the N-terminal GTPase domain regulated inflammatory factor production. These findings elucidate gGBP1's multifaceted mechanisms in curbing inflammation and viral replication.
 
gGBP1 as a Therapeutic Target
Understanding gGBP1's role in modulating inflammatory responses opens avenues for targeted therapies against IAV infections. By harnessing gGBP1's inhibitory effects, novel treatment strategies can be developed to mitigate cytokine storms and improve clinical outcomes.
 
Potential Clinical Applications
The findings suggest that enhancing gGBP1 expression or activity could serve as a therapeutic approach in managing severe influenza cases. Combining antiviral agents with gGBP1-targeted interventions may offer synergistic benefits in combating IAV-induced complications.
 
The elucidation of gGBP1's role in modulating inflammatory responses and viral replication has significant implications for therapeutic interventions in influenza infections. Targeting gGBP1 or its downstream signaling pathways could offer novel strategies for mitigating cytokine storms and reducing disease severity. Moreover, combining gGBP1-targeted therapies with existing antiviral agents may synergistically enhance treatment efficacy and improve clinical outcomes.
 
Future Directions and Challenges
While the role of gGBP1 in influenza infection is becoming clearer, several challenges and avenues for future research remain. Further investigations are needed to unravel the precise molecular mechanisms underlying gGBP1's actions and its interactions with viral proteins. Additionally, exploring the potential synergies between gGBP1-targeted therapies and immunomodulatory agents could lead to more comprehensive treatment approaches.
 
Conclusion
Guanylate-binding protein 1 emerges as a key player in modulating inflammatory responses and limiting H5N1-induced pathogenesis. Its multifaceted functions, from inhibiting viral replication to regulating cytokine production, highlight its therapeutic potential in combating severe influenza infections. Continued research on gGBP1 holds promise for developing innovative strategies to mitigate inflammatory complications and enhance patient outcomes in IAV infections.
 
The study findings were published in the peer reviewed journal: Poultry Science.
https://www.sciencedirect.com/science/article/pii/S0032579124003791
 
For the latest H5N1 News, keep on logging to Thailand Medical News.

MOST READ

Nov 05, 2024  9 days ago
Nikhil Prasad
Jul 25, 2024  4 months ago
Nikhil Prasad
Jul 24, 2024  4 months ago
Nikhil Prasad
Jun 10, 2023  1 year ago
COVID-19 News - DNA Methylation - Asymptomatic SARS-CoV-2 Infections
Aug 04, 2022  2 years ago
Source: Medical News - SARS-CoV-2 & Cancer